LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS
Pre-Launchlamivudine; nevirapine; zidovudine
NDAORALTABLET, FOR SUSPENSIONPriority Review
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
Priority Review
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS (lamivudine; nevirapine; zidovudine) by Matrix Surgical USA is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE is a fixed-dose combination oral tablet containing three HIV-1 antiretroviral agents for treatment of HIV-1 infection in adults and pediatric patients weighing at least 6 kg. The combination leverages nucleoside reverse transcriptase inhibitors (lamivudine, zidovudine) and a non-nucleoside reverse transcriptase inhibitor (nevirapine) to suppress viral replication through complementary mechanisms of action.
Pre-Launch
Pre-launch stage indicates opportunity for launch-focused roles; commercial team size will scale post-approval depending on market reception against established competitors.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.